Determinants of overweight and obesity and other cardiometabolic risks in adolescents: a Spanish longitudinal birth study
July 18, 2025 / adolescent obesity / cardiometabolic risk / prenatal health / physical activity / dietary impact
Pre-pregnancy obesity, maternal smoking, and adolescent diet and activity significantly influence cardiometabolic risks and obesity patterns by age 15, underscoring the need for early, multi-stage prevention strategies.
Study Investigates Long-Term Cardiometabolic Impact of Early-Onset Obesity
July 18, 2025 / early obesity / biological aging / cardiometabolic health / insulin resistance / metabolic dysfunction
Early-onset, long-term obesity in young adults is linked to accelerated biological aging and worsened cardiometabolic markers, increasing risk for chronic disease and underscoring the importance of early intervention.
Extracellular vesicle RNA reveals clues about obesity and metabolic disease
July 15, 2025 / extracellular vesicles / obesity biomarkers / type 2 diabetes / adipose RNA / functional genomics
This study identifies extracellular vesicle RNA as a reflection of obesity-related gene activity in adipose tissue, offering a novel genomic tool for understanding, diagnosing, and potentially treating obesity and type 2 diabetes.
Obesity, Depression, and Antidepressant Use: Analyzing Metabolic Side Effects in US Adults Using the National Health and Nutrition Examination Survey (NHANES)
July 17, 2025 / antidepressant effects / metabolic health / obesity risk / depression treatment / NHANES study
Antidepressant use is linked to specific metabolic changes—such as elevated cholesterol—particularly in women and non-depressed individuals, though not directly to obesity. These findings highlight the need for metabolic monitoring during antidepressant therapy across diverse patient populations.
Polyoxometalate-based hybrid nanovesicles offer dual-action therapy for obesity-related metabolic disorders
July 15, 2024 / nanomedicine therapy / obesity treatment / insulin resistance / inflammation control / metabolic health
Researchers developed polyoxometalate-based nanovesicles that stabilize and deliver PAHSA lipids to metabolic tissues, enhancing insulin signaling and reducing inflammation—offering a dual-action, non-injectable therapeutic strategy for obesity-related metabolic disorders.
Experts highlight urgent need to regulate bariatric and metabolic surgery medical tourism
July 16, 2025 / bariatric tourism / obesity surgery / patient safety / global regulation / medical ethics
Unregulated bariatric surgery tourism poses significant health, safety, and ethical risks. Experts urge global regulatory oversight to ensure appropriate care, informed consent, and postoperative follow-up, as demand rises despite access to weight loss medications.
Long sitting hours raise breast cancer odds for inactive obese women
July 15, 2025 / breast cancer risk / sedentary lifestyle / physical activity / obesity in women / cancer prevention
Prolonged sitting significantly increases breast cancer prevalence in physically inactive obese women, but this risk is mitigated by regular physical activity. Findings highlight sedentary behavior as a modifiable risk factor, especially in postmenopausal and high-BMI populations.
Your internal clock sets meal times that lower risk of obesity and diabetes
July 18, 2025 / MASH treatment / GLP-1 agonists / liver fibrosis / resmetirom therapy / metabolic liver disease
MASH, a progressive form of MASLD, involves increased hepatic lipogenesis and inflammation. Emerging treatments include resmetirom, GLP-1/GIP agonists, and pioglitazone. Combination therapies and agents like FGF21 analogues show promise for fibrosis reversal and long-term liver health improvement.
Weight-loss drug Tirzepatide significantly slows breast cancer growth, study finds
July 15, 2025 / tirzepatide therapy / breast cancer growth / obesity treatment / GLP-1 agonists / metabolic oncology
Tirzepatide, a GLP-1/GIP receptor agonist, significantly reduced breast tumor growth and body fat in obese mice, suggesting potential anti-cancer benefits beyond weight loss. Ongoing studies aim to clarify its role in obesity-associated cancer risk reduction.
Detecting Portal Venous Blood Flow in Metabolic Dysfunction-Associated Fatty Liver Disease Using Non-Invasive Doppler Ultrasound
July 21, 2024 / MAFLD detection / Doppler ultrasound / portal blood flow / liver disease monitoring / non-invasive imaging
Non-invasive Doppler ultrasound detected feeding-state changes in portal venous blood flow but failed to distinguish MAFLD-induced differences seen with invasive methods. While promising for early monitoring, further validation is needed to enhance clinical accuracy in liver disease detection.
McKinsey Health Institute says weight management drugs could lead to a metabolic health revolution
July 18, 2025 / GLP-1 drugs / metabolic health / obesity prevention / longevity innovation / public health strategy
GLP-1-based weight loss drugs may catalyze a global metabolic health revolution, potentially preventing obesity-related disease and adding up to 469 million healthy life years. Success depends on broad cross-sector collaboration, sustained investment, and scalable public health strategies.
SpaceGut Marks World Microbiome Day with Science-Backed Solution for Malaysia’s Obesity Issue
July 17, 2025 / gut microbiome / obesity Malaysia / personalised nutrition / metabolic health / microbiota testing
SpaceGut targets Malaysia’s obesity crisis by offering a gut microbiome test and AI-driven dietary plans, addressing microbial imbalances linked to weight gain, inflammation, and appetite regulation—demonstrating significant weight loss through personalised, microbiota-informed nutrition.
Metabolic dysfunction linked to surge in gallstone disease, finds study
July 16, 2025 / gallstone disease / metabolic dysfunction / obesity diabetes / MASLD risk / digestive health
Gallstone disease prevalence is rising in the U.S., strongly linked to obesity, diabetes, hypertension, and MASLD. These associations are particularly pronounced in women and adults under 60, highlighting the metabolic origins of gallstone formation.
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis
July 21, 2025 / semaglutide MASH / liver fibrosis reversal / metabolic inflammation / GLP-1 therapy / proteomic biomarkers
Semaglutide improves liver inflammation and fibrosis in MASH by modulating metabolic, inflammatory, and fibrotic pathways. Proteomic profiling reveals a reversal of disease-associated protein signatures, suggesting semaglutide may restore a healthy metabolic and inflammatory state in MASH patients.
How a Hidden Hand of Hepatic Signaling Could Help Fight Metabolic Disease
July 21, 2025 / PTPRD liver function / metabolic liver disease / MASH treatment / STAT3 signaling / insulin resistance
PTPRD, a liver protein, suppresses pro-inflammatory STAT3 signaling and supports lipid metabolism and insulin sensitivity. Its deficiency accelerates MASH progression, identifying PTPRD as both a potential therapeutic target and biomarker in metabolic liver disease.
Madrigal receives patent allowance for MASH treatment Rezdiffra
July 16, 2025 / Rezdiffra approval / MASH treatment / resmetirom patent / liver fibrosis therapy / THR-β agonist
Madrigal Pharmaceuticals secured U.S. patent protection for Rezdiffra, the first FDA-approved treatment for MASH with moderate to advanced fibrosis. The THR-β agonist targets disease mechanisms and is under evaluation for broader use in cirrhotic MASH patients.
Multidimensional links between dietary behavior and cardiometabolic comorbidities: a network analysis
July 18, 2025 / cardiometabolic risk / unhealthy diet / NAFLD prevalence / network analysis / early intervention
Network analysis among working-age adults identified frequent meat consumption, dining out, and late-night eating as central dietary behaviors linked to cardiometabolic comorbidities, including NAFLD, hypertension, and diabetes—highlighting actionable targets for early metabolic disease prevention.
These 4 habits in middle age have the ‘greatest impact’ on your heart health: study
July 20, 2025 / menopause heart risk / cardiovascular disease / blood pressure control / smoking cessation / sleep and heart health
A study finds that sleep quality, blood pressure, blood glucose, and smoking are the most impactful lifestyle factors for heart health in menopausal women. Targeting these can significantly reduce cardiovascular disease risk during midlife transitions.
“Forever Chemicals” Linked to Higher Risk of Type 2 Diabetes
July 20, 2025 / PFAS exposure / type 2 diabetes / environmental toxins / metabolic disruption / forever chemicals
Mount Sinai researchers found that higher blood levels of PFAS, or “forever chemicals,” are linked to a 31% increased risk of developing type 2 diabetes, likely through disruption of metabolic pathways, including amino acid biosynthesis and drug metabolism.
New study could help doctors address diabetes, prediabetes
July 21, 2025 / continuous glucose monitoring / prediabetes reversal / metabolic health / personalized nutrition / type 2 diabetes prevention
Stanford researchers used continuous glucose monitoring to reveal individualized metabolic responses to carbohydrates, uncovering distinct pathways to prediabetes and type 2 diabetes. These insights support precision nutrition and lifestyle interventions to reverse or prevent metabolic dysfunction.